Results 161 to 170 of about 58,406 (311)

Managing Treatment‐Emergent Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CAR‐T Cell Therapy: A Case‐Based Review of the use of Emapalumab

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapies have revolutionized the treatment of hematological malignancies, achieving high response rates in patients with relapsed or refractory disease. Despite these benefits, CAR‐T cell therapies are associated with unique toxicities, including cytokine release syndrome (CRS), immune effector cell ...
Livia Donzelli, Veronica Zullino, Giovanni Fernando Torelli, Maria Stefania De Propris, Mario Piazzolla, Franco Ruberto, Maurizio Martelli, Alice Di Rocco   +7 more
wiley   +1 more source

TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B‐Cell Lymphoma in the Real‐Life Patient Journey

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT The combination of tafasitamab and lenalidomide (tafa‐lena) has demonstrated efficacy in relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL), as evidenced by the L‐MIND study. To investigate the therapeutic potential and safety profile of tafa‐lena in real‐life, we conducted a national multicentric retrospective study.
Lisa Argnani, Cinzia Pellegrini, Ombretta Annibali, Piera Angelillo, Enrico Amaducci, Filippo Ballerini, Flaminia Bellisario, Andrea Bernardelli, Riccardo Bruna, Catello Califano, Giusy Cetani, Giulia Daghia, Enrico Derenzini, Antonio Frolli, Francesco Gaudio, Valerio Guarente, Ausilia Gorgone, Liardo Eliana Valentina, Elisa Lucchini, Dario Marino, Luca Nassi, Paolo Nicoli, Mattia Novo, Francesca Palombi, Caterina Patti, Vincenzo Pavone, Marcello Riva, Filomena Russo, Greta Scapinello, Alessandro Severino, Monica Tani, Daniele Vallisa, Beatrice Casadei, Alessandro Broccoli, Pier Luigi Zinzani   +34 more
wiley   +1 more source

Association Between Adiposity and Low Total Serum Bilirubin Concentration: A Retrospective, Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims Bilirubin, an antioxidant and anti‐inflammatory agent, has been shown to negatively correlate with adiposity. However, the extent to which adiposity level influences total bilirubin (TBili) concentration remains unclear. We sought to evaluate the associations of body mass index (BMI; kg/m²) and waist circumference (WC) with
Trishna Parikh, Fariha Hameed, Sumaiya Islam, Shivani Reddy, Eshani Goradia, Bhargav Vemulapalli, Aayush Visaria   +6 more
wiley   +1 more source

A new type of constitutional hyperbilirubinemia with unconjugated bilirubin-A case of nonhemolytic hyperbilirubinemia with marked retention of sulfobromophthalein test

, 1980
Masaji Nambu, Chikako Ueda, Koki YOSHIMURA, Ryuichi Sakita, Sanpei HISHINUMA, Hiroshi Ueyama, Ayako Morikawa, Masatake Takagi, Hideo UEDA, Akira Asahara, Hiroshi Ishihara, Yuji YAMASHIRO, Norio Kobayashi, Hiroyuki Kuroda, Toshihiko Namihisa   +14 more
openalex   +2 more sources

Anti‐Tubercular Drug‐Induced Liver Injury: Current Understanding and Emerging Directions

JGH Open, Volume 10, Issue 1, January 2026.
ABSTRACT Most common adverse effect causing cessation of anti‐tubercular treatment (ATT) is drug‐induced liver injury (DILI) which is unpredictable due to its idiosyncratic nature. ATT is the most common cause of DILI and drug‐induced acute liver failure (ALF) in South East Asia.
Shubham Prasad, Himanshu Narang, Saurabh Kedia, Vineet Ahuja   +3 more
wiley   +1 more source

Hyperbilirubinemia and appendicular perforation peritonitis

, 2020
Rajandeep Singh Gupta, Shyam Gupta, Asim Rafiq Laharwal   +2 more
openalex   +2 more sources

Pregnancies in Women With Long‐Chain Fatty Acid Oxidation Disorders: Results of a European and North American Survey

Journal of Inherited Metabolic Disease, Volume 49, Issue 1, January 2026.
ABSTRACT Long‐chain fatty acid oxidation disorders (lcFAODs) are genetic disorders of energy metabolism that are associated with a risk of metabolic decompensation, especially during catabolic episodes. With improvement in diagnostics and treatment, more women with lcFAODs now reach child‐bearing age.
Sarah C. Grünert, Mirjam Langeveld, Lisa Rudolph, Ute Spiekerkoetter, Allan M. Lund, Annalisa Sechi, Halil Tuna Akar, Karolina M. Stepien, Hanım Aghakishili, Amelie S. Lotz‐Havla, Klaus G. Parhofer, Saadet Mercimek‐Andrews, Havva Yazıcı, Sema Kalkan Uçar, Thomas Scherer, Margreet Wagenmakers, Nur Arslan, Irene Chang, Allie LaTray, Vladimir Bzduch, Ivo Barić, Corina Weigel, Sonja. L. van Ockenburg, Alexander Rennings, Terry G. J. Derks, Alessandro Rossi, David Cassiman, Elaine Murphy   +27 more
wiley   +1 more source

Hyperbilirubinemia

Canadian family physician Medecin de famille canadien, 2012
  +6 more sources

A Multisystem Perspective of Pediatric Cell Trafficking Disorders: Within the Cells, Beneath the Signs

JIMD Reports, Volume 67, Issue 1, January 2026.
ABSTRACT Cell trafficking disorders(CTDs) are rare, heterogeneous inherited conditions marked by impaired intracellular transport mechanisms such as vesicular trafficking, cytoskeletal dynamics, and organelle interactions. Although clinical awareness is increasing, CTDs are often underdiagnosed due to phenotypic overlap with mitochondrial, lysosomal ...
Merve Yoldaş Çelik, Burcu Köşeci, Ezgi Burgaç, Kanay Yararbaş, Tamer Çelik, Esra Sarıgeçili, Habibe Koç Uçar   +6 more
wiley   +1 more source

Postpartum related intrahepatic cholangiocarcinoma with FGFR2 fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review

, 2023
Leslie Washburn, Amit Mahipal, Aminah Jatoi, Lisa A. Kottschade, Nguyen H. Tran   +4 more
openalex   +1 more source